In which group of patients is Prolia primarily used?

Prolia, also known as denosumab, is primarily indicated for postmenopausal women and men at risk for fractures due to conditions like osteoporosis. This medication works by inhibiting RANKL, a protein involved in bone resorption, which helps to increase bone density and reduce the risk of fractures. The use of Prolia is particularly crucial in populations that have a higher risk of osteoporosis, such as postmenopausal women, who experience a significant decrease in estrogen levels that contribute to bone loss, as well as men who may have similar risk factors.

The other groups listed are not the primary focus for Prolia use. Children with asthma would not be treated with Prolia, as it is not indicated for conditions related to respiratory issues. Individuals with cardiovascular disease are not specifically targeted with this medication, as Prolia does not address cardiovascular conditions. Lastly, while elderly patients with arthritis may have various concerns about bone health, Prolia's primary indication is not for arthritis management but rather for osteoporosis and fracture risk reduction in specific populations. Thus, the correct group benefiting from Prolia is indeed postmenopausal women and men at risk for fractures.